Chen Chun-Rong, Aliesky Holly A, Guo Jin, Rapoport Basil, McLachlan Sandra M
Autoimmune Disease Unit, Cedars-Sinai Research Institute and UCLA School of Medicine, Los Angeles, California, USA.
Thyroid. 2006 May;16(5):427-34. doi: 10.1089/thy.2006.16.427.
Immune responses require costimulatory interactions between molecules on antigen-presenting cells and T cells: CD40 binding to CD40 ligand and B7 binding to CD28. Graves' hyperthyroidism is induced in BALB/c mice by immunization with thyrotropin receptor (TSHR) A-subunit adenovirus (Ad-A-subunit). We attempted to modulate Ad-A-subunit-induced Graves' disease using adenoviruses expressing costimulation "decoys": CD40-IgG-Fc (CD40-Ig) to block CD40:CD40-ligand interactions and CTLA4-Fc (CTLA4-Ig) to prevent B7:CD28 binding.
Unexpectedly, coimmunizing mice with Ad-A-subunit and excess control adenovirus (1:10 Ad-A-subunit:Ad-control) reduced TSHR antibody levels (thyrotropin binding inhibition [TBI]). Furthermore, only 15% of mice developed hyperthyroidism versus 75% using the same Ad-A-subunit dose (10(8) particles) without Ad-control. This effect was related to the dose of control adenovirus but not to the adenovirus insert, the timing or immunization site. Increasing the Ad-subunit dose (10(9) particles) and decreasing the control adenovirus dose (10:1 Ad-A-subunit:Ad-control) induced high TBI levels and 80% of mice were hyperthyroid. Coimmunization with Ad-CD40-Ig (but not Ad-CTLA4-Ig) reduced the incidence of hyperthyroidism to 40%.
Using appropriate controls and adenovirus ratios, our data suggest the importance of CD40:CD40-ligand interactions for inducing Graves' hyperthyroidism by Ad-A-subunit. Furthermore, our observations emphasize the potential pitfalls of non-specific inhibition by coimmunization with two adenovirus species.
免疫反应需要抗原呈递细胞和T细胞上的分子之间的共刺激相互作用:CD40与CD40配体结合以及B7与CD28结合。通过用促甲状腺素受体(TSHR)A亚基腺病毒(Ad-A亚基)免疫BALB/c小鼠可诱发格雷夫斯甲状腺功能亢进症。我们试图使用表达共刺激“诱饵”的腺病毒来调节Ad-A亚基诱导的格雷夫斯病:CD40-IgG-Fc(CD40-Ig)以阻断CD40:CD40配体相互作用,CTLA4-Fc(CTLA4-Ig)以防止B7:CD28结合。
出乎意料的是,将Ad-A亚基与过量对照腺病毒(1:10 Ad-A亚基:Ad-对照)共同免疫小鼠可降低TSHR抗体水平(促甲状腺素结合抑制率[TBI])。此外,只有15%的小鼠发生甲状腺功能亢进症,而使用相同剂量(10⁸个颗粒)的Ad-A亚基且无Ad-对照时,这一比例为75%。这种效应与对照腺病毒的剂量有关,而与腺病毒插入片段、免疫时间或免疫部位无关。增加Ad亚基剂量(10⁹个颗粒)并降低对照腺病毒剂量(10:1 Ad-A亚基:Ad-对照)会导致高TBI水平,80%的小鼠出现甲状腺功能亢进症。与Ad-CD40-Ig(而非Ad-CTLA4-Ig)共同免疫可将甲状腺功能亢进症的发生率降低至40%。
使用适当的对照和腺病毒比例,我们的数据表明CD40:CD40配体相互作用对于Ad-A亚基诱导格雷夫斯甲状腺功能亢进症的重要性。此外,我们的观察结果强调了用两种腺病毒共同免疫进行非特异性抑制时潜在的陷阱。